Introducing treatment strategy for cerebellar ataxia in mutant med mice: Combination of acetazolamide and 4-Aminopyridine

被引:3
作者
Abbasi, Samira [1 ]
Abbasi, Ataollah [1 ]
Sarbaz, Yashar [2 ]
机构
[1] Sahand Univ Technol, Fac Elect Engn, Dept Biomed Engn, Computat Neurosci Lab, Tabriz, Iran
[2] Univ Tabriz, Sch Engn Emerging Technol, Tabriz, Iran
关键词
Ataxia; Neuroprotective agents; Modeling; Therapeutics; Ion channels; CHANNEL BLOCKER 4-AMINOPYRIDINE; AMYOTROPHIC-LATERAL-SCLEROSIS; RESURGENT SODIUM CURRENT; PURKINJE NEURONS; EPISODIC ATAXIA; MULTIPLE-SCLEROSIS; POTASSIUM CHANNELS; K+ CHANNELS; RILUZOLE; RAT;
D O I
10.1016/j.cmpb.2013.11.008
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Purkinje neurons are the sole output neuron of the cerebellar cortex, and they generate high-frequency action potentials. Electrophysiological dysfunction of Purkinje neurons causes cerebellar ataxia. Mutant med mice have the lack of expression of the Scn8a gene. This gene encodes the NaV1.6 protein. In med Purkinje neurons, regular high-frequency firing is slowed, and med mice are ataxic. The aim of this study was to propose the neuroprotective drugs which could be useful for ataxia treatment in med mice, and to investigate the neuroprotective effects of these drugs by simulation. Simulation results showed that Kv4 channel inhibitors and BK channel activators restored the normal electrophysiological properties of the med Purkinje neurons. 4-Aminopyridine (4-AP) and acetazolamide (ACTZ) were proposed as neuroprotective drugs for Kv4 channel inhibitor and BK channel activator, respectively. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:697 / 704
页数:8
相关论文
共 45 条
[1]   Interaction of Kv3 potassium channels and resurgent sodium current influences the rate of spontaneous firing of Purkinje neurons [J].
Akemann, W ;
Knopfel, T .
JOURNAL OF NEUROSCIENCE, 2006, 26 (17) :4602-4612
[2]  
AL H, 1952, J PHYSL, V117, P500
[3]   KCa Channels as Therapeutic Targets in Episodic Ataxia Type-2 [J].
Alvina, Karina ;
Khodakhah, Kamran .
JOURNAL OF NEUROSCIENCE, 2010, 30 (21) :7249-7257
[4]  
ALZHEIMER C, 2003, MOL CELLULAR BIOL NE, V513
[5]   A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
BENSIMON, G ;
LACOMBLEZ, L ;
MEININGER, V ;
BOUCHE, P ;
DELWAIDE, C ;
COURATIER, P ;
BLIN, O ;
VIADER, F ;
PEYROSTPAUL, H ;
DAVID, J ;
MALOTEAUX, JM ;
HUGON, J ;
LATERRE, EC ;
RASCOL, A ;
CLANET, M ;
VALLAT, JM ;
DUMAS, A ;
SERRATRICE, G ;
LECHEVALLIER, B ;
PEUCH, AJ ;
NGUYEN, T ;
SHU, C ;
BASTIEN, P ;
PAPILLON, C ;
DURRLEMAN, S ;
LOUVEL, E ;
GUILLET, P ;
LEDOUX, L ;
ORVOENFRIJA, E ;
DIB, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :585-591
[6]   Voltage-gated sodium channel blockers, 2001-2006:: An overview [J].
Bolcskei, Hedvig ;
Tarnawa, Istvan ;
Kocsis, Pal .
MEDICINAL CHEMISTRY RESEARCH, 2008, 17 (2-7) :356-368
[7]   Acetazolamide-responsive episodic ataxia in an Italian family refines gene mapping on chromosome 19p13 [J].
Calandriello, L ;
Veneziano, L ;
Francia, A ;
Sabbadini, G ;
Colonnese, C ;
Mantuano, E ;
Jodice, C ;
Trettel, F ;
Viviani, P ;
Manfredi, M ;
Frontali, M .
BRAIN, 1997, 120 :805-812
[8]  
Camerino DC, 2007, NEUROTHERAPEUTICS, V4, P184
[9]   Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole [J].
Cao, YJ ;
Dreixler, JC ;
Couey, JJ ;
Houamed, KM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (1-2) :47-54
[10]   4-AMINOPYRIDINE IN THE TREATMENT OF ALZHEIMERS-DISEASE [J].
DAVIDSON, M ;
ZEMISHLANY, Z ;
MOHS, RC ;
HORVATH, TB ;
POWCHIK, P ;
BLASS, JP ;
DAVIS, KL .
BIOLOGICAL PSYCHIATRY, 1988, 23 (05) :485-490